Leveraging the Genomics of Drug Sensitivity database (https://www.cancerrxgene.org/), RAS mutations were also seen to confer resistance in AML cell lines with NRAS mutations significantly mutated in midostaurin resistant cell lines (p = 0.003) [38] Combined, these findings suggest the involvement of Ras-Raf-MEK-ERK pathway as a possible escape mechanism for midostaurin therapy. The gene discussed is NRAS; the disease is acute myeloid leukemia.